OncoMatch/Clinical Trials/NCT06393738
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
Is NCT06393738 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including ARV-393 and Glofitamab for relapsed/refractory (r/r) mature b cell non hodgkin lymphoma (nhl).
Treatment: ARV-393 · Glofitamab — This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma (R/R NHL) to determine if ARV-393 may be a possible treatment option. ARV-393 is thought to work by breaking down a protein present in many types of non-Hodgkins lymphomas, which may prevent, slow or stop tumor growth. This is the first time ARV-393 will be used by people. The investigational drug will be given as an oral tablet.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy (rituximab)
relapsed/refractory NHL and 2 prior systemic therapies, (including rituximab)
Cannot have received: allogeneic stem cell transplant
Prior allogeneic stem cell transplant (SCT)
Cannot have received: solid organ transplantation
Prior...solid organ transplantation
Lab requirements
Blood counts
Adequate bone marrow function
Kidney function
Adequate kidney function
Liver function
Adequate Liver Function
Cardiac function
Cardiac ejection fraction <45% excluded; no clinically relevant ECG abnormalities; no serious conduction system abnormalities; no symptomatic CHF NYHA Class III or IV
Adequate bone marrow function; Adequate kidney function; Adequate Liver Function; Standard 12-lead electrocardiogram (ECG) that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results; Cardiac ejection fraction <45%.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Clinical Trial Site · New Haven, Connecticut
- Clinical Trial Site · Detroit, Michigan
- Clinical Trial Site · New Brunswick, New Jersey
- Clinical Trial Site · New York, New York
- Clinical Trial Site · New York, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06393738 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogeneic stem cell transplant, solid organ transplantation disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages